InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial
September 22, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”). The clinical trial is designed to evaluate the efficacy of TRYP’s clinical candidate, TRP-8802, for the treatment of patients […]
InvestorNewsBreaks – Sprout AI Inc. (CSE: SPRT) Selected as Cultivation Technology of Choice by JT Medical LLC
September 21, 2021
Sprout AI (CSE: SPRT), a technologically focused, sustainable vertical farming company that has developed scalable, controlled aeroponic cultivation habitats, leverages AI technology designed to provide solutions to the ever-increasing complexities surrounding the current and future supply of a sustainable global food production and supply chain. The company today announced that it has been selected as […]
Sprout AI Inc. Announces Initial Sales Order
September 21, 2021
VANCOUVER, British Columbia, Sept. 21, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Sprout AI Inc. (“Sprout AI” or the “Company”) (CSE: SPRT) is a technologically focused, sustainable vertical farming company that has developed scalable, controlled aeroponic cultivation habitats. Sprout AI’s technology will provide solutions to the ever increasing complexities surrounding the current and future supply of a sustainable global food […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Planned Acquisition of Ketamine Wellness Centers Inc.
September 20, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced plans to merge with Ketamine Wellness Centers Arizona LLC (“KWC”), which would create the largest psychedelic wellness chain in the country. The binding merger agreement would create 12 open locations — 10 KWC locations and two Delic locations — with plans in place to […]
InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Exec to Participate in Upcoming in Mental Health Virtual Conference
September 17, 2021
Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has announced that president and CEO Kelsey Ramsden will be participating in the Advances in Mental Health Virtual Conference. The one-day conference, presented by Maxim Group LLC and hosted by M-Vest, is scheduled for Sept. 22, […]
Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)
September 17, 2021
Pharmaceutical company Tryp Therapeutics is pursuing novel solutions to medical conditions with unmet needs, working to establish the efficacy and safety of the company’s trademarked synthetic psychedelic drug candidate The company’s products — TRP-8802 and TRP-8803 — aim to provide new therapies for select eating disorders with specific neurological causes, as well as pain and […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Participation in Oppenheimer Fall Healthcare Summit
September 16, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, will be a featured presenter at the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. The three-day event, scheduled for Sept. 20–23, 2021, will be a virtual event. Tryp CEO and chair Greg McKee […]
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Likely to Benefit from New Research Touting Psilocybin Mental Health Treatments
September 14, 2021
Yale researchers publish study that a single dose of psilocybin counteracts symptoms of depression Administering drug to mice resulted in an approximately 10% increase in neuron size and density Cybin is focused on progressing psychedelic therapeutics As news of psychedelic research continues to report breakthroughs — such as the recent news from a group of Yale researchers […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Innovation, Partnerships, and Leadership: A 2021 Outlook
September 13, 2021
So far in 2021, Tryp’s innovations have allowed it to position itself as a first-mover in the psychedelics space The company has announced completion of psychotherapy training for the upcoming phase 2a clinical trials for specific overeating disorders Tryp has also been keen on collaborating and partnering with key players in the industry, such as […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Keynote Speaker Chris Ryan, Ph.D., for World’s Premiere Psychedelic and Wellness Event
September 10, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced that Chris Ryan, Ph.D., will serve as one of the headline speakers on Nov. 7, 2021, at Meet Delic, the largest and most comprehensive event to learn about the intersection of psychedelics, wellness and business. In his keynote, “Psychedelics and […]
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) CEO Discusses Psychedelics, Company’s Progress, Plans, Business in a Recent Bell2Bell Podcast Interview
September 10, 2021
Mind Cure Health Inc. CEO Kelsey Ramsden was featured in a recent Bell2Bell podcast interview, during which she explained the company’s primary focal points – digital therapeutics and drug development On the digital therapeutics side of its business, the company is developing iSTRYM, a clinical-grade, evidence-backed, science-based, AI-driven tool for both therapists and patients, scheduled […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share Updates on Its PFN Program Pipeline at the Upcoming H.C Wainwright 23rd Annual Global Investor Conference
September 9, 2021
Tryp Therapeutics is set to present at the H.C Wainwright 23rd Annual Global Investor Conference scheduled for Sept. 13-15, 2021 Greg McKee, company chairman and CEO, will provide an overview of the business and its pipeline, including the Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program Tryp’s presentation will be available on-demand from 7.00 a.m. EDT on Sept. 13 […]
InvestorNewsBreaks – Why Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is ‘One to Watch’
September 8, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is committed to bringing science-backed benefits to all and reframing the psychedelic conversation. “The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the first psychedelic umbrella platform. It is currently a trusted source […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Training for Upcoming Phase 2a Psychedelics Trial Targeting Eating Disorders
September 8, 2021
Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needs The company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Positioned as First Mover in Psychedelics Space
September 7, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was recently hosted by Oren Klaff on the Dealmaker Podcast. The interview, which illuminated Tryp Therapeutics’ operations and McKee’s personal story on how he ended up as the CEO, offered some great insights into the future of the psychedelics space, along with what ordinary people can […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Featured in Article as Stock That Is ‘Shaping up to Be a Brilliant Investment’
September 3, 2021
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company focused on advancing psychedelic pharmaceutical therapeutics for various psychiatric and neurological conditions, was highlighted in a Motley Fool article titled, “Buying Cybin Stock Right Now Could Be a Brilliant Move.” The piece, written by Alex Carchidi, delves into CYBN as one of those investment opportunities […]
Perpetual Industries Inc. (PRPI) Names Seasoned Data Scientist to Team
September 1, 2021
Christopher Thurber brings impressive expertise in software engineering, machine learning, IT and security analysis Thurber’s primary responsibility will be working on PRPI’s proprietary AutoGrafic Software System Thurber’s depth of experience is particularly valuable as the company just completed acquisition of the AutoGrafic Software System earlier this year Perpetual Industries (OTC: PRPI) has announced that Christopher […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright Global Investment Conference
September 1, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced that it will present at the H.C. Wainwright Annual Global Investment Conference. The event is slated to be held virtually on Sept. 13-15, 2021. Greg McKee, chairman and CEO […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Meet Delic Keynote Speaker
September 1, 2021
Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has revealed the keynote speaker for its upcoming Meet Delic event. Renowned shaman and best-selling author Alyson Charles will speak at the two-day immersive edutainment experience that is designed as an elite gathering for the world’s leading psychedelic and wellness thought and business […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Part 2 in ‘History of Psychedelics’ Content Series
August 30, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, partnered with Visual Capitalist to create a two-part, data-driven content series and graphic that takes a look at how psychedelics have evolved over the last 6,000 years. The second part specifically […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), At the Forefront of the Psychedelic Renaissance
August 27, 2021
Psychedelics date back to ancient times, with records showing their use among the Aztecs as well as cultures in North Africa and Europe for medicinal and cultural purposes The prohibition era marked significant strides in psychedelics research, including the ultimate prohibition of the possession, sale and manufacture of psychedelics The 21st century has seen a […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Equity Research Report
August 27, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, was featured in a recent equity research report. The coverage, initiated by Ladenburg Thalmann & Co. Inc., highlights Tryp Therapeutics’ efforts to reset the treatment of various disorders through the novel dosing of formulations of […]
InvestorNewsBreaks – Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF) Appoints Members to Newly Formed Medical Advisory Board
August 26, 2021
Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has created a Medical Advisory Board to advise the company and its subsidiaries in developing safety protocols and best practices. Board members include an impressive array of medical professionals including a neuroscientist, anesthesiologist, addiction psychiatrist, interventional pain physician and more. These board members […]
InvestorNewsBreaks – Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF) Meet Delic Event to Feature Award-Winning Investigative Reporter as Keynote Speaker
August 24, 2021
Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced one of its headline speakers for its upcoming Meet Delic event. Award-winning investigative reporter Ben Westhoff will present a keynote address titled “Fentanyl in Our Drugs,” which will discuss how fentanyl is upending the entire recreational drug landscape. His presentation includes a […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Psychotherapy Training for Upcoming Clinical Trial
August 24, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced it has completed the training of psychotherapists for its upcoming phase 2a clinical trial using synthetic psilocybin in combination with psychotherapy for overeating disorders. According to the update, the training was conducted by […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Visual Capitalist Article
August 23, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was recently featured as a sponsored content provider on the Visual Capitalist. In the article, part one of a two-part series titled, “The History of Psychedelics (Part 1 of 2),” Tryp […]
Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is ‘One to Watch’
August 19, 2021
Delic is led by a best-in-class team of industry veterans with over 100 years of working knowledge in cannabis, finance, and psychedelic research The Vancouver-based company was formed in 2019 as the first psychedelic umbrella platform The Delic self-sustaining Ecosystem covers three main areas: media, health, and science On March 4, 2021, Delic announced its […]
InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Co-Founder, CEO Featured on Bell2Bell Podcast
August 19, 2021
Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, has announced that co-founder and CEO Kelsey Ramsden is featured on the latest episode of the Bell2Bell podcast. The Bell2Bell Podcast offers its listeners insightful interviews with executives of companies operating in fast-moving industries. During the episode, hosted […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with Calvert Labs, Gad Consulting Services to Conduct Preclinical Bridging Studies in Preparation for Phase 2b Clinical Trials
August 19, 2021
Tryp Therapeutics recently announced new agreements with Calvert Labs and Gad Consulting Services, the second in a series of upcoming bridging studies aimed at facilitating the advancement of TRP-8803 into Phase 2b clinical trials Calvert Labs will design and execute the exploratory studies, while Gad Consulting Services will advise on certain aspects of the studies […]
InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Kelsey Ramsden, Co-Founder & CEO of Mind Cure Health Inc.
August 19, 2021
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) — via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Standing Distinct in Psychedelic-Derived Treatments Space
August 17, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is focused on driving significant innovation with its drug development pipeline. Tryp is leveraging its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program in the development of treatments for chronic pain indications including fibromyalgia, phantom limb pain and complex regional pain syndrome. In addition, the company is preparing to initiate a phase 2a […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Keynote Speaker for Upcoming Psychedelic and Wellness Event – Meet Delic
August 17, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that Laura Dawn, Msc. will serve as one of the headlining speakers at Meet Delic on Nov. 6, 2021. According to the update, her keynote, “Exploring the Intersection Between Psychedelics & Creative Problem Solving,” targets business and thought-leaders, entrepreneurs and creators. “Laura […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Insights on the Psychedelics Space on The Dealmaker Podcast
August 13, 2021
Mr. Greg McKee, CEO of Tryp Therapeutics, appeared on The Dealmaker Podcast to share insights on the company and the psychedelics industry During the interview, he discussed the potential of psychedelics in the treatment of PTSD and other mental disorders Greg also shared the challenges that the industry is facing currently, mostly to do with […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Headline Speaker for Upcoming Psychedelic and Wellness Event – Meet Delic
August 12, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that Luke Storey will serve as one of the headline speakers at Meet Delic. The world’s premiere psychedelic and wellness edutainment event, Meet Delic caters to curious newcomers as well as business and thought leaders. A motivational speaker, meditation and metaphysics teacher […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Partnerships to Explore, Develop Proprietary Psilocybin Formulations
August 10, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, has signed agreements with both Calvert Labs and Gad Consulting Services to design, execute and collaborate on exploratory studies related to Tryp’s Psilocybin-for-Neuropsychiatric Disorders, or PFN(TM) (“PFN”), program. An Altasciences company, Calvert Labs […]
InvestorNewsBreaks – Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF) Scientific Advisor Granted Full Professorship
August 10, 2021
Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced that Glenn Sammis, a professor and scientific advisor to subsidiary Delic Labs, has received a full professorship at the University of British Columbia in the chemistry department. The announcement also noted that Sammis will be working closely with Dr. Markus Roggen in developing intellectual property (“IP”) […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present Flagship PFN Program at 2021 Canaccord Genuity Virtual Growth Conference
August 5, 2021
The company will present an overview of business operations and its pipeline, including the Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders The initial indication of lead drug candidate TRP-8802 is for fibromyalgia, but Tryp believes that psilocybin can be used for much more in the realm of unmet medical needs PFN’s development […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured on The Dealmaker Show, to Present at Canaccord Genuity Annual Growth Conference
August 3, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was featured on The Dealmaker Show, a fast-paced and high-energy forum hosted by bestselling author Oren Klaff. Tryp’s CEO and Chairman Greg McKee joined the latest episode to discuss the company’s […]
InvestorBrandNetwork Announces The Dealmaker Show Interview with Tryp Therapeutics Inc. CEO Greg McKee
August 3, 2021
LOS ANGELES, Aug. 03, 2021 (GLOBE NEWSWIRE) — via InvestorWire –InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that Greg McKee, Chairman & CEO of Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs, recently appeared on The Dealmaker Show, a fast-paced and […]
Mark Haden, Psychedelic Medicine Expert, Joins Clearmind Medicine’s Advisory Board
August 3, 2021
Toronto, Aug. 03, 2021 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announces that Mark Haden has joined the Company’s Scientific Advisory Board (the “SAB”). The SAB’s initial focus […]